Protocol for EKC/ Betadine Treatment

1. Determine eligibility:
   - At least 18 years of age
   - Has clinical signs and symptoms compatible with EKC
   - Symptomatic for less than 5 days
   - Has the ability to understand and give signed informed consent
   - No ocular surgery within the last 3 months
   - No active ocular allergies
   - Has not used any topical ocular medication (pharmacologic agent) during the prior 30 days
   - No history of hypersensitivity to iodine

2. Print out informed consent form, review with patient, and have patient sign for your office record.

3. Initial encounter
   - Obtain history:
     - Duration of symptoms prior to presentation
     - Subjective severity of symptoms:
       - None, mild, moderate, or severe:
         - Itching
         - Tearing
         - Burning
         - Swelling
         - Discharge
     - Positive or negative:
       - Recent history of upper respiratory infection
   - Examination:
     - Snellen visual acuity
     - External/slit lamp examination
       - Positive or negative:
         - Preauricular adenopathy
       - Grade 0, 1, 2, or 3 (none, mild, moderate, or severe):
         - Lid edema
         - Discharge
         - Conjunctival membranes
         - Conjunctival injection
         - Conjunctival chemosis
         - Conjunctival follicular response
         - Corneal infiltration
       - Note any other significant findings
     - Adjunctive/confirmatory testing

        - If available, perform RPS (rapid pathogen screening) for adenoviral infection

3. Treatment technique with Betadine 5% wash
    - Instill 3 drops of tetracaine in the eye(s) to be treated
    - Instill 5 drops of Betadine 5% into the treatment eye(s)
    - Instruct patient to close eye(s) and move side to side, up and down for 60 seconds to facilitate even dispersal throughout ocular surface; use gloved finger to spread Betadine over lid margin and lashes to eradicate any virus on external adnexa.
    - After 60 seconds, thoroughly rinse eye with sterile eyewash until all traces of Betadine have been removed
    - Patient should be scheduled for follow up: 2-3 days, 4-5 days, and 7-14 days post treatment.

4. Follow-up encounters
    - Obtain history:
        - Subjective severity of symptoms:
            - None, mild, moderate, or severe:
                - Itching
                - Tearing
                - Burning
                - Swelling
                - Discharge
    - Examination:
        - Snellen visual acuity
        - External/slit lamp examination
            - Positive or negative:
                - Preauricular adenopathy
            - Grade 0, 1, 2, or 3 (none, mild, moderate, or severe):
                - Lid edema
                - Discharge
                - Conjunctival membranes
                - Conjunctival injection
                - Conjunctival chemosis
                - Conjunctival follicular response
                - Corneal infiltration
            - Note any other significant findings
    - Grade clinical picture compared to previous encounters
        - Better, worse, unchanged, or resolved

5. Data submission can be performed through online system after registering at www.betadineforekc.com. Patients will be assigned a unique identifier and will become anonymous in the system. This identifier should be recorded by the investigator and recorded in the office chart; it is used to perform data recall and subsequent data editing.